Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Analysis: 75+ Key Companies Advancing 300+ Pipeline Therapies for COPD Treatment | DelveInsight

DelveInsight's Chronic Obstructive Pulmonary Disease (COPD) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline COPD therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the COPD pipeline domain.

Key takeaways from the COPD Clinical Trial Landscape Report
• DelveInsight's COPD pipeline report depicts a robust space with 75+ active players working to develop 300+ pipeline therapies for Chronic Obstructive Pulmonary Disease treatment.
• Key COPD companies such as GSK, AstraZeneca, Amgen, Sanofi/Regeneron, Uniquity Bio, Bambusa Therapeutics, and SpliSense, and others.
• Promising COPD pipeline therapies in various stages of development include Tezepelumab, Itepekimab, GSK3511294, Solrikitug, SPL5AC, and others.

Request a sample and discover the recent advances in COPD treatment drugs at: https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Chronic Obstructive Pulmonary Disease (COPD)?
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable chronic inflammatory lung disease characterized by persistent and progressive airflow limitation caused by an enhanced inflammatory response in the airways and lungs due to noxious particles or gases. COPD mainly includes emphysema and chronic bronchitis.
According to the World Health Organization (WHO), COPD is the third leading cause of death worldwide. Excessive smoking remains the leading risk factor for COPD, while occupational and environmental exposure to chemical fumes, dust, and lung irritants account for a substantial proportion of cases. Symptoms include chronic cough, dyspnea, sputum production, and airflow obstruction. Diagnosis is based on spirometry, imaging tests, and clinical evaluation. Current treatment approaches include bronchodilators, corticosteroids, antibiotics, ventilatory support, and chest physical therapy.

Emerging COPD Drug Profiles

Tezepelumab: Amgen/AstraZeneca
TEZSPIRE (tezepelumab-ekko) is a human monoclonal antibody administered through subcutaneous injection. It targets thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in multiple inflammatory pathways associated with airway inflammation. The therapy is jointly developed by Amgen and AstraZeneca and is currently in Phase III development for Chronic Obstructive Pulmonary Disease treatment.
In March 2025, AstraZeneca in collaboration with Amgen initiated a Phase III multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of tezepelumab in adults with moderate to very severe COPD. The study is anticipated to enroll 990 participants and is expected to be completed by March 2029.

Itepekimab: Sanofi/Regeneron
Itepekimab is an interleukin-33 inhibitor being investigated for the treatment of Chronic Obstructive Pulmonary Disease. The therapy is currently in Phase III development and is being evaluated for its ability to reduce moderate and severe COPD exacerbations in former smokers with inadequately controlled disease.

Learn more about the novel and emerging COPD pipeline therapies at: https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the COPD Clinical Trial Landscape
• In October 2025, GSK plc and Empirico Inc announced a worldwide exclusive license agreement for EMP-012, a highly selective siRNA therapy currently in Phase I clinical development for COPD.
• On May 30, 2025, the AERIFY-1 Phase III study evaluating itepekimab met the primary endpoint with a statistically significant 27% reduction in moderate or severe acute COPD exacerbations compared to placebo at week 52.
• In July 2024, Amgen announced that the US Food and Drug Administration granted Breakthrough Therapy Designation to TEZSPIRE as an add-on maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype.
• In 2020, Amgen and AstraZeneca updated their collaboration agreement for TEZSPIRE, continuing joint development and commercialization activities globally.

Scope of the COPD Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Preclinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Inhalation, Oral, Intravenous, Intranasal, Parenteral, Subcutaneous, Sublingual
• Therapeutics Assessment By Molecule Type: Antibody, Small molecule, Vaccine, Protein, Peptide, Cell Therapy, SiRNA, Immunoglobulin, and others
• Key COPD Companies: GSK, AstraZeneca, Amgen, Sanofi/Regeneron, Uniquity Bio, Bambusa Therapeutics, SpliSense, and others
• Key COPD Pipeline Therapies: Tezepelumab, Itepekimab, GSK3511294, Solrikitug, SPL5AC, and others

Dive deep into rich insights for new drugs for COPD treatment at: https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. COPD Pipeline Report Introduction
2. COPD Pipeline Report Executive Summary
3. COPD Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. COPD Pipeline Therapeutics
6. COPD Pipeline: Late Stage Products (Phase III)
7. COPD Pipeline: Mid Stage Products (Phase II)
8. COPD Pipeline: Early Stage Products (Phase I)
9. COPD Pipeline Therapeutics Assessment
10. Inactive Products in the COPD Pipeline
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products in the COPD Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the COPD pipeline therapeutics, reach out to DelveInsight at: https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.